By Suherman Candra Maholtra 
Groundbreaking research conducted by scientists at the University of Virginia School of Medicine has identified a significant link between severe respiratory viral infections, such as COVID-19 and influenza, and the long-term development of lung cancer. The study, led by Dr. Jie Sun and published in the prestigious scientific journal Cell, suggests that the physiological aftermath of a severe infection can create a "pro-tumor" environment within the lungs, potentially accelerating cancer progression months or even years after a patient has recovered from the initial illness.
The findings from UVA Health’s Beirne B. Carter Center for Immunology Research and the UVA Comprehensive Cancer Center have immediate implications for clinical practice, particularly regarding how survivors of severe respiratory distress are monitored. Crucially, the research also highlights the role of vaccination in mitigating these long-term risks, offering a secondary layer of protection beyond the prevention of acute illness.
The Mechanistic Link: How Infection Seeds Future Malignancy
The core of the study revolves around the discovery that severe respiratory infections do more than cause temporary damage to lung tissue; they fundamentally alter the immune landscape of the organ. Researchers found that a "bad case" of COVID-19 or the flu leaves the lungs in a chronic state of inflammation. This persistent inflammatory environment acts as a catalyst, making it significantly easier for cancerous cells to take root and proliferate.
Dr. Jie Sun, who serves as the co-director of UVA’s Carter Center and is a member of the Division of Infectious Diseases and International Health, explained that the immune response intended to fight off a virus can sometimes backfire if the infection is sufficiently severe. This results in "immune scarring," where the cells meant to protect the body instead foster an environment conducive to tumor growth.
The study utilized a dual-track approach, combining controlled laboratory experiments on mice with an extensive analysis of human clinical data. In the animal models, mice that survived severe viral pneumonia exhibited a marked increase in the development of lung tumors compared to those that were not infected. Furthermore, these infected mice showed higher mortality rates once cancer was established, suggesting that the post-viral environment not only helps cancer start but also helps it spread more aggressively.
Quantitative Data: The 1.24-Fold Increase in Cancer Risk
To validate the findings observed in the laboratory, the UVA team analyzed vast datasets of human patients who had been hospitalized with COVID-19. The statistical analysis revealed a striking 1.24-fold increase in the incidence of lung cancer among patients who had experienced severe bouts of the virus.
Significantly, this elevated risk was observed across diverse patient demographics. The data held true regardless of whether the individuals were smokers or had other pre-existing medical conditions, known as comorbidities. This suggests that the severe viral infection itself is an independent risk factor for lung cancer, functioning similarly to traditional carcinogens by altering the cellular environment of the lungs.
Conversely, the researchers noted a distinct difference in outcomes for those who experienced only mild infections. Patients with mild cases of COVID-19 did not show an increased risk of lung cancer. In some instances, these patients actually showed a slight decrease in cancer incidence, though the researchers focused primarily on the danger posed by severe, hospitalized cases.
Cellular Alterations: Neutrophils and "Pro-Tumor" Environments
The researchers delved deep into the cellular changes that drive this increased risk. By examining the lungs at a microscopic level, they identified major abnormalities in immune cells known as neutrophils and macrophages. Under normal conditions, these cells are the body’s first line of defense against pathogens. However, following a severe infection, certain neutrophils began behaving abnormally.
Instead of returning to a resting state after the virus was cleared, these neutrophils contributed to a persistent, pro-tumor inflammatory state. This environment is characterized by the release of specific signaling molecules that suppress the body’s natural anti-cancer immune responses while simultaneously promoting the growth of blood vessels that feed tumors.
The study also identified significant changes in the epithelial cells—the cells that line the lungs and the alveoli (the tiny air sacs where oxygen exchange occurs). These structural cells showed signs of long-term damage and "remodeling" after severe infection, further contributing to a landscape where cancer could more easily develop.
Shifting Clinical Protocols: Monitoring the Post-Viral Patient
The implications for medical professionals are profound. Currently, lung cancer screening is largely dictated by a patient’s age and smoking history. However, the UVA study suggests that a history of severe respiratory viral infection should perhaps be treated with similar gravity.
Dr. Jeffrey Sturek, a UVA physician-scientist and collaborator on the study, noted that the medical community has long recognized smoking as a primary risk factor necessitating routine screening, such as low-dose CT scans. "The results from this study suggest that we may need to think about severe respiratory viral infection similarly," Sturek said. He suggested that in the future, patients who have survived severe viral pneumonia might benefit from enhanced surveillance to catch potential lung cancers in their earliest, most treatable stages.
This proactive approach could be vital for the tens of millions of people worldwide who have suffered from severe COVID-19 or "Long COVID" pulmonary sequelae. By identifying these individuals as a high-risk group, doctors can implement earlier interventions that could save lives.
Vaccination as Indirect Cancer Prevention
One of the most encouraging aspects of the study is the finding that vaccination significantly mitigates the risk of post-viral cancer development. The researchers observed that prior vaccination blocked many of the harmful lung changes associated with tumor growth.
While vaccines are primarily designed to prevent acute infection and death, this research suggests they offer "indirect cancer protection." By ensuring that an infection remains mild rather than severe, vaccines prevent the massive immune system overreaction and subsequent "immune scarring" that creates the pro-tumor environment.
"The encouraging news is that vaccination largely prevents those harmful changes for cancer growth in the lung," Dr. Sun emphasized. This adds a new dimension to the public health argument for routine vaccination against influenza and COVID-19, framing it not just as a defense against respiratory illness, but as a long-term strategy for cancer prevention.
Chronology of Research and Institutional Support
The study represents a multi-year effort that began during the height of the COVID-19 pandemic. As hospitals were flooded with patients suffering from viral pneumonia, researchers at UVA began to wonder about the long-term "shadow" these infections would cast on public health.
The research was made possible through the collaboration of several high-level institutions within the University of Virginia system. The Paul and Diane Manning Institute of Biotechnology played a crucial role in accelerating the translation of these laboratory findings into potential clinical applications. The institute’s mission is to bridge the gap between complex biomedical research and real-world medical treatments.
Furthermore, the UVA Beirne B. Carter Center for Immunology Research provided the specialized expertise needed to decode the complex immune responses involved. The UVA Comprehensive Cancer Center, one of only 57 centers in the U.S. to hold a "comprehensive" designation from the National Cancer Institute, provided the oncological framework for the study.
The research was supported by extensive funding from the National Institutes of Health (NIH), along with several specialized grants, including the UVA Pinn Scholar Award and the American Lung Association Catalyst Grant. The diverse range of funding sources reflects the interdisciplinary nature of the work, touching on immunology, oncology, and infectious disease.
Broader Impact and Future Directions
The publication of these findings in Cell marks a significant milestone in our understanding of the relationship between infectious diseases and chronic conditions. While the link between certain viruses and cancer is well-established—such as HPV and cervical cancer or Hepatitis B and liver cancer—this study provides some of the first concrete evidence that common respiratory viruses like the flu can also influence cancer risk through indirect environmental changes in the lung.
Looking forward, Dr. Sun and his colleagues aim to develop targeted therapies that can "reset" the lung’s immune environment after a severe infection. If scientists can find a way to prevent or reverse the immune scarring and neutrophil dysfunction identified in this study, they may be able to eliminate the increased cancer risk entirely for survivors of severe pneumonia.
"Our goal is to help doctors identify who may be at higher risk of lung cancer after a severe infection and develop targeted ways to prevent and treat lung cancer after prior pneumonia," Sun concluded.
As the world continues to navigate the post-pandemic era, this research serves as a critical reminder of the long-term health consequences of severe viral infections. It underscores the vital importance of vaccination, the need for continued vigilance in patient monitoring, and the potential for innovative biotechnology to solve some of the most complex challenges in modern medicine. For patients who have survived the worst of COVID-19 or the flu, the message from UVA is clear: recovery is the first step, but long-term lung health requires ongoing attention and proactive care.
